{"id":"dl-methylphenidate-plus-cannabidiol","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Appetite suppression"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL796","moleculeType":"Small molecule","molecularWeight":"233.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Methylphenidate is a sympathomimetic amine that blocks the reuptake of dopamine and norepinephrine, enhancing attention and executive function. Cannabidiol (CBD) acts as a modulator of cannabinoid receptors and other targets (5-HT1A, TRPV1), providing anxiolytic and anti-inflammatory effects. The combination is designed to leverage methylphenidate's cognitive enhancement while CBD may mitigate potential anxiety or adverse effects from stimulant use.","oneSentence":"dl-Methylphenidate increases dopamine and norepinephrine availability in the central nervous system, while cannabidiol modulates endocannabinoid signaling and has anti-inflammatory properties.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:37:03.089Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Attention-deficit/hyperactivity disorder (ADHD) with anxiety or comorbid conditions"}]},"trialDetails":[{"nctId":"NCT04603391","phase":"PHASE4","title":"Cannabidiol and CES1 Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"University of Florida","startDate":"2021-02-25","conditions":"Drug Interaction","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ritalin®","Epidiolex®"],"phase":"marketed","status":"active","brandName":"dl-Methylphenidate plus Cannabidiol","genericName":"dl-Methylphenidate plus Cannabidiol","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"dl-Methylphenidate plus Cannabidiol is being studied for its potential drug interaction effects in healthy subjects. This combination is a small molecule that inhibits the sodium-dependent dopamine transporter, a mechanism associated with dl-Methylphenidate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}